These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 25972243

  • 1. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A, Zhang L, Boufraqech M, Zhang Y, Patel D, Shen M, Kebebew E.
    Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
    Zhang L, Boufraqech M, Lake R, Kebebew E.
    Oncotarget; 2016 Mar 29; 7(13):16517-28. PubMed ID: 26934320
    [Abstract] [Full Text] [Related]

  • 4. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E.
    Oncotarget; 2015 Apr 20; 6(11):9073-85. PubMed ID: 25940539
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.
    Mehta A, Zhang L, Boufraqech M, Liu-Chittenden Y, Zhang Y, Patel D, Davis S, Rosenberg A, Ylaya K, Aufforth R, Li Z, Shen M, Kebebew E.
    Clin Cancer Res; 2015 Sep 15; 21(18):4123-32. PubMed ID: 25944801
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.
    J Nucl Med; 2012 Nov 15; 53(11):1764-71. PubMed ID: 23055533
    [Abstract] [Full Text] [Related]

  • 9. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W, Zhou J, Zhao L, Chen S.
    Biomed Pharmacother; 2017 Apr 15; 88():985-990. PubMed ID: 28178630
    [Abstract] [Full Text] [Related]

  • 10. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 11. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X, Park S, Lee WK, Cheng SY.
    Endocr Relat Cancer; 2019 Sep 01; 26(9):739-750. PubMed ID: 31272080
    [Abstract] [Full Text] [Related]

  • 12. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.
    Oncol Rep; 2018 May 01; 39(5):2225-2234. PubMed ID: 29517103
    [Abstract] [Full Text] [Related]

  • 13. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
    Mi L, Liu J, Zhang Y, Su A, Tang M, Xing Z, He T, Wei T, Li Z, Wu W.
    Phytomedicine; 2024 Jul 01; 129():155670. PubMed ID: 38704915
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS.
    Clin Cancer Res; 2016 Dec 15; 22(24):6192-6203. PubMed ID: 27307592
    [Abstract] [Full Text] [Related]

  • 15. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K, Sato F, Tamagawa S, Gunduz M, Onoda N, Uchino S, Muragaki Y, Hotomi M.
    Sci Rep; 2019 Oct 10; 9(1):14616. PubMed ID: 31601917
    [Abstract] [Full Text] [Related]

  • 16. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A.
    Endocrine; 2016 Jul 10; 53(1):136-44. PubMed ID: 26286966
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
    Lin SF, Yeh CN, Huang YT, Chou TC, Wong RJ.
    Cancer Sci; 2021 Feb 10; 112(2):803-814. PubMed ID: 33306266
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.